How to Cite
Abstract
.
Colorectal cancer (CRC) is a heterogeneous disease with a myriad of cellular and molecular alterations. KRAS mutations occur in nearly one in two patients with CRC and serve as both prognostic and predictive biomarkers. Patients with KRASG12C are a distinct prognostically unfavourable cohort, accounting for approximately 4% of all cases. Several KRASG12C allele-specific inhibitors are currently in phase III clinical trials, and new drugs and treatment strategies are being actively investigated. In this article, we analyse current treatment approaches for patients with KRAS-mutant mCRC.
References
Martianov A.S., Mitiushkina N.V., Ershova A.N., et al. KRAS, NRAS, BRAF, HER2 and MSI status in a large consecutive series of colorectal carcinomas. Int J Mol Sci. 2023; 24(5): 4868.-DOI: 10.3390/ijms24054868.
Cremolini C., Antoniotti C., Stein A., et al. Individual patient data meta-analysis of FOLFOXIRI plus bevacizumab versus doublets plus bevacizumab as initial therapy of unresectable metastatic colorectal cancer. J Clin Oncol. 2020: JCO2001225.-DOI: 10.1200/JCO.20.01225.
Douillard J.Y., Oliner K.S., Siena S., et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013; 369(11): 1023-34.-DOI: 10.1056/NEJMoa1305275.
Heinemann V., von Weikersthal L.F., Decker T., et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014; 15(10): 1065-75.-DOI: 10.1016/S1470-2045(14)70330-4.
Van Cutsem E., Yaeger R., Delord J.P., et al. Phase Ib/II Study of the efficacy and safety of binimetinib (MEK162) plus panitumumab for mutant or wild-type RAS metastatic colorectal cancer. Oncologist. 2023; 28(12): e1209-e1218.-DOI: 10.1093/oncolo/oyad210.
Bennouna J., Sastre J., Arnold D., et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2013; 14(1): 29-37.-DOI: 10.1016/S1470-2045(12)70477-1.
Fernández Montes A., Martínez Lago N., Covela Rúa M., et al J. Efficacy and safety of FOLFIRI/aflibercept in second-line treatment of metastatic colorectal cancer in a real-world population: Prognostic and predictive markers. Cancer Med. 2019; 8(3): 882-889.-DOI: 10.1002/cam4.1903.
Obermannová R., van Cutsem E., Yoshino T., et al. Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression. Ann Oncol. 2016; 27(11): 2082-2090.-DOI: 10.1093/annonc/mdw402.
Федянин М.Ю. Современная клиническая и молекулярно-биологическая платформа лечения пациентов раком толстой кишки: дис. … д-ра мед. наук. М., 2018. 414 c. [Fedyanin M.Yu. Modern clinical and molecular biological platform for the treatment of patients with colon cancer: dis. ... Doctor of Medical Sciences, Moscow. 2018.;414 (In Rus)].
Osumi H., Takashima A., Ooki A., et al. A multi-institutional observational study evaluating the incidence and the clinicopathological characteristics of NeoRAS wild-type metastatic colorectal cancer. Transl Oncol. 2023; 35: 101718.-DOI: 10.1016/j.tranon.2023.101718.
Albuquerque J., Neto da Silva D., Padrão T., et al. Loss of RAS mutations in liquid biopsies of patients with multi-treated metastatic colorectal cancer. Oncologist. 2024; 29(3): e337-e344.-DOI: 10.1093/oncolo/oyad299.
Harada K., Yuki S., Kawamoto Y., et al. Anti-epidermal growth factor receptor treatment for patients with NeoRAS wild-type metastatic colorectal cancer: a case report of two cases. Ther Adv Med Oncol. 2023; 15: 17588359231216090.-DOI: 10.1177/17588359231216090.
Eng C., Kim T.W., Bendell J., et al. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2019; 20(6): 849-861.-DOI: 10.1016/S1470-2045(19)30027-0.
Grothey A., Van Cutsem E., Sobrero A., et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013; 381(9863): 303-12.-DOI: 10.1016/S0140-6736(12)61900-X.
Li J., Qin S., Xu R., et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2015; 16(6): 619-29.-DOI: 10.1016/S1470-2045(15)70156-7.
Mayer R.J., van Cutsem E., Falcone A., et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015; 372(20): 1909-19.-DOI: 10.1056/NEJMoa141432.
van de Haar J., Ma X., Ooft S.N., et al. Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer. Nat Med. 2023; 29(3): 605-614.-DOI: 10.1038/s41591-023-02240-8.
Prager G.W., Taieb J., Fakih M., et al. Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer. N Engl J Med. 2023; 388(18): 1657-1667.-DOI: 10.1056/NEJMoa2214963.
Tabernero J., Taieb J., Fakih M., et al. Impact of KRASG12 mutations on survival with trifluridine/tipiracil plus bevacizumab in patients with refractory metastatic colorectal cancer: post hoc analysis of the phase III SUNLIGHT trial. ESMO Open. 2024; 9(3): 102945.-DOI: 10.1016/j.esmoop.2024.102945.
Basso M., Signorelli C., Calegari M.A., et al. Efficacy of regorafenib and trifluridine/tipiracil according to extended RAS evaluation in advanced metastatic colorectal cancer patients: a multicenter retrospective analysis. Target Oncol. 2024; 19(3): 371-382.-DOI: 10.1007/s11523-024-01050-3.
Nevala-Plagemann C., Sama S., Ying J., et al. A real-world comparison of regorafenib and trifluridine/tipiracil in refractory metastatic colorectal cancer in the United States. J Natl Compr Canc Netw. 2023; 21(3): 257-264.-DOI: 10.6004/jnccn.2022.7082.
Kim R., Tehfe M., Kavan P., et al. Pembrolizumab Plus mFOLFOX7 or FOLFIRI for microsatellite stable/mismatch repair-proficient metastatic colorectal cancer: KEYNOTE-651 cohorts B and D. Clin Colorectal Cancer. 2024; 23(2): 118-127.e6.-DOI: 10.1016/j.clcc.2024.03.001.
Edin S., Gylling B., Li X., et al. Opposing roles by KRAS and BRAF mutation on immune cell infiltration in colorectal cancer — possible implications for immunotherapy. Br J Cancer. 2024; 130(1): 143-150.-DOI: 10.1038/s41416-023-02483-9.
Damato A., Bergamo F., Antonuzzo L., et al. Phase II study of nivolumab in combination with FOLFOXIRI/bevacizumab as first-line treatment in patients with advanced colorectal cancer RAS/BRAF mutated (mut): NIVACOR trial (GOIRC-03-2018). J Clin Oncol. 2022; 40: 16_suppl, 3509-3509.-DOI: 10.1200/JCO.2022.40.16_suppl.3509.
Lenz H.J., Parikh A., Spigel D.R., et al. Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial. J Immunother Cancer. 2024; 12(3): e008409.-DOI: 10.1136/jitc-2023-008409.
Thibaudin M., Fumet J.D., Chibaudel B., et al. First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial. Nat Med. 2023; 29(8): 2087-2098.-DOI: 10.1038/s41591-023-02497-z.
Ostrem J.M., Peters U., Sos M.L., et al. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature. 2013; 503(7477): 548-51.-DOI: 10.1038/nature12796.
Yaeger R., Weiss J., Pelster M.S., et al. Adagrasib with or without cetuximab in colorectal cancer with mutated KRAS G12C. N Engl J Med. 2023; 388(1): 44-54.-DOI: 10.1056/NEJMoa2212419.
Hong D.S., Fakih M.G., Strickler J.H., et al. KRASG12C inhibition with sotorasib in advanced solid tumors. N Engl J Med. 2020; 383(13): 1207-1217.-DOI: 10.1056/NEJMoa1917239.
Sacher A., LoRusso P., Patel M.R., et al. Single-agent divarasib (GDC-6036) in solid tumors with a KRAS G12C mutation. N Engl J Med. 2023; 389(8): 710-721.-DOI: 10.1056/NEJMoa2303810.
Kuboki Y., Fakih M., Strickler J., et al. Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial. Nat Med. 2024; 30(1): 265-270.-DOI: 10.1038/s41591-023-02717-6.
Hong D.S., Kuboki Y., Strickler J.H., et al. Sotorasib (Soto) plus panitumumab (Pmab) and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreaK 101 phase 1b safety and efficacy. J Clin Oncol. 2023; 41: 16_suppl, 3513-3513.-DOI: 10.1200/JCO.2023.41.16_suppl.3513.
Fakih M.G., Salvatore L., Esaki T., et al. Sotorasib plus panitumumab in refractory colorectal cancer with mutated KRAS G12C. N Engl J Med. 2023; 389(23): 2125-2139.-DOI: 10.1056/NEJMoa2308795.
Desai J., Alonso G., Kim S.H., et al. Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial. Nat Med. 2024; 30(1): 271-278.-DOI: 10.1038/s41591-023-02696-8.
Ran Z., Chen W., Shang J., et al. Clinicopathological and prognostic implications of polo-like kinase 1 expression in colorectal cancer: A systematic review and meta-analysis. Gene. 2019; 721: 144097.-DOI: 10.1016/j.gene.2019.144097.
Ahn D.H., Barzi A, Ridinger M, et al. Onvansertib in combination with FOLFIRI and bevacizumab in second-line treatment of KRAS-mutant metastatic colorectal cancer: a phase Ib clinical study. Clin Cancer Res. 2024; 30(10): 2039-2047.-DOI: 10.1158/1078-0432.CCR-23-3053.
Li J., Qin S., Xu R.H., et al. Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: The FRESCO randomized clinical trial. JAMA. 2018; 319(24): 2486-2496.-DOI: 10.1001/jama.2018.7855.
Dasari A., Lonardi S., Garcia-Carbonero R., et al. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet. 2023; 402(10395): 41-53.-DOI: 10.1016/S0140-6736(23)00772-9.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2025